Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDOT: Neoadjuvant Nivolumab in Urothelial Cancer
NCT04871594Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in urothelial carcinoma (UC), sponsored by Netherlands Cancer Institute. Primary endpoint: Feasibility of pre-operative nivolumab at 12 weeks. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04871594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871594.